Cancer is a disease that results from the breakdown of several checkpoints and tumor-suppressing mechanisms. 1 Every year nearly 10.9 million people are diagnosed with cancer worldwide, and 6.7 million people die from the disease, making cancer the second largest cause of death next to cardiovascular diseases. 2 The World Health Organization predicts that this grim statistic will be even worse and incidence of cancer may increase by 50% in the year 2020. Despite significant advances in cancer diagnostics and therapy there is still little progress in the treatment of advanced stages of the disease. Therefore, it is imperative to find better ways to cure cancer. 3 Fortunately, despite the high incidence of cancer; human cells have developed intrinsic cellular and molecular mechanisms against tumors. One of the most intensively studied cellular molecules protecting the cell against malignant transformation is a single protein, the tumor suppressor p53.
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The tumor suppressor p53 is a potent transcription factor that controls a major pathway protecting cells from malignant transformation. 5, 6 As such, it is the most frequently inactivated protein in human cancer. 7 In response to stress, the cellular level of p53 is elevated by a posttranslational mechanism, leading to cell cycle arrest or apoptosis. Under nonstressed conditions, p53 is tightly controlled by the MDM2 protein through an autoregulatory feedback loop. [8] [9] [10] [11] [12] p53 can activate MDM2 expression, which in turn, leads to the repression of p53 by three mechanisms. First, MDM2 binds p53 at its transactivation domain and blocks its ability to activate transcription. Second, it is involved in the nuclear export of p53. Third, it serves as an E3 ubiquitin ligase that promotes p53 degradation. 13 The mdm2 gene has been found amplified or overexpressed in a number of human malignancies. 14, 15 The p53-MDM2 interaction is the best characterized of all MDM2 interactions and offers a logical target for exploitation in cancer therapy. Several recent studies have shown that disruption of the p53-MDM2 interaction by different macromolecular approaches or by the suppression of MDM2 expression can lead to the activation of p53 and tumor growth inhibition. [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] One attractive pharmacological approach to p53 re-activation is to use a small molecule to block the MDM2-p53 interaction. 16, 26, 27 Small molecule drugs are attractive because of several advantages they have over large molecules like peptides, antibodies and polynucleotides (antisense oligonucleotides, ribozymes, siRNA etc.,), such as better stability, delivery and bioavailability (especially oral bioavailability), as well as less stringent regulatory control and lower production costs.
Protein-protein interactions are generally difficult to inhibit with small molecules due to factors such as large and shallow interaction interfaces that often lack deep binding pockets. Such surfaces are difficult to cover with small molecules, although progress has been made in this area. 28, 29 However, in the case of p53-MDM2 binding at the N-terminal of MDM2, the interface is relatively small, and has a deep, well-defined basin-like cleft with well-defined hydrophobic pockets 30 that small molecules can bind with high affinity and effectively compete against p53 binding. Early successful studies with p53-derived peptides [31] [32] [33] that effectively disrupted the MDM-p53 interaction opened the door for harnessing the interaction for therapeutic purposes. The assays that were developed through the peptide studies, i.e., ELISA and gel mobility shift assays 32, 33 have paved the way for the search for inhibitors. Thus, several classes of compounds have been reported to exhibit high-affinity competitive binding to the p53 binding site on MDM2, and leading to p53 accumulation, enhanced cell cycle arrest and/or apoptosis in cancer cells. [34] [35] [36] [37] [38] [39] The increasing number of small molecule p53-MDM2 inhibitors can be attributed to more sophisticated structure-based drug design tools and better assays.
Are Small Molecules Suitable Drugs for Cancer Chemotherapy?
The discovery of the Nutlins provides the important proof of the concept for this approach. 37 Nutlins were shown to bind to MDM2, block the MDM2-p53 interaction and activate wild-type p53. 37, [40] [41] [42] One critical question in the development of MDM2 inhibitors for cancer treatment is their potential toxicity to normal tissues. This concern was heightened by a recent genetic study, which showed that p53 activation in the absence of the MDM2 gene causes
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Inhibition of MDM2-p53 feedback loop by various small molecules for potential cancer chemotherapy severe toxicity to radiosensitive normal adult mouse tissues, leading to rapid animal death. 43 Previous studies on Nutlin-3 reported that therapeutically effective doses do not cause animal weight loss or other gross abnormalities, 37, 40 but whether an MDM2 inhibitor would activate p53 and cause toxicity in normal tissues remains unaddressed. For an unambiguous evaluation of pharmacological activation of p53 by blocking the MDM2-p53 interaction, it is essential first to create an ideal small molecule with the following properties: (i) a high binding affinity to MDM2, (ii) excellent specificity for MDM2 over other proteins, (iii) potent cellular activity and specificity, and (iv) a highly desirable pharmacokinetic (PK) profile in animals for in vivo evaluation.
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In this report, MI inhibited the growth of A549 and H460 cells harboring wt p53 and this inhibition was largely abolished upon siRNA silencing of p53. The mechanism of the growth inhibition in these cells appears to be mediated by p53 activation, followed by p21 induction to arrest cells at the G 1 or G 2 phase at a low drug concentration. MI-43 induced both growth arrest and apoptosis in a dose dependent manner in H460 cells. At lower drug concentrations, MI-43 induced a remarkable induction of p21 leading to 90% of cells arresting at the G 1 phase without apparent apoptosis, although Puma and Noxa were also induced. At higher concentrations, the induced p21 level was relatively lower and cells underwent apoptosis even with a moderate further increase of Puma and Noxa. Similarly, in A549 cells, MI-43 at low concentration induced a high level of p21 with a remarkable G 2 /M arrest, but not apoptosis. At a high concentration, MI-43 induced a lower amount of p21, whereas the levels of Puma and Noxa were moderately increased resulting in apoptosis. Their observation in lung cancer cells is consistent with the observation made in colon cancer cells that induction of both Puma and Noxa caused apoptosis when p21 level was relatively low, suggesting the balance between Puma and Noxa is pivotal in determining cellular responses to p53 activation. 44 MI-43 was less toxic to MRC5 fetal lung fibroblasts harboring wt p53. Interestingly, MRC5 expressed a very high basal level of p53, which was not further induced by MI-43. Lack of p53 activation was further confirmed by a failure of MI-43 to induce Mdm2, p21 and Puma. Consequently, MRC5 was very resistant to MI-43 with an IC 50 one magnitude higher than wt p53 containing lung cancer cells. As was observed in p53 null cancer cells, the cytotoxic effect of MI-43 in MRC5 cells is likely p53-independent and is associated with non-specific drug activity. Furthermore, they determined that MI-43 sensitizes A549 cells to etoposide-induced apoptosis. In chemo-resistant A549 cells, the combination of MI-43 with etoposide yielded a synergistic effect on apoptosis induction, as demonstrated by three independent assays, including western blotting to show higher levels of Puma induction, caspase-3 activation and PARP cleavage; FACS analysis to show a significant increase of sub-G 1 population; and caspase-3 activity assay to show a up to 10-fold activation.
It is unclear in the study by what mechanism etoposide failed to induce MDM2 after inducing p53 and how it reduced the level of MI-43-induced MDM2. Nevertheless, reduction of MDM2, a negative regulator of p53, would certainly further increases p53 activity and apoptosis, leading to a synergistic effect. Thus, MI-43 and etoposide worked in a synergistic manner to achieve a maximal killing of otherwise resistant A549 cells.
Earlier, the same research groups led by Wang and Sun 45 also developed MI-219 as another potent, highly selective and orally active small-molecule inhibitor of the MDM2-p53 interaction. MI-219 appears to be a second generation of MI-43 and binds to human MDM2 with a K i value of 5 nM and is 10,000-fold more selective for MDM2 than MDMX. MI-219 disrupts the MDM2-p53 interaction and activates the p53 pathway in cells with wild-type p53. Activation of p53 by MI-219 leads to cell cycle arrest in both normal and tumor cells and selective apoptosis in the latter. It activates p53 in normal mouse tissues with minimal p53 accumulation and is not toxic to animals, indicating that normal cells and tissues are intrinsically resistant to activation of p53 by an MDM2 inhibitor. MI-219 stimulates rapid but transient p53 activation in xenograft tumor tissues, resulting in inhibition of cell proliferation, induction of apoptosis, and complete tumor growth inhibition consistent with the notion that established tumors remain persistently vulnerable to the p53 tumor-suppressor function. 46 The small molecule inhibitors of the MDM2-p53 interaction discussed here have shown p53-dependent activity in multiple cellular models, strongly implying that their antitumor mechanism is dependent on the activation of the p53 pathway. The data strengthen the notion that unleashing the powerful growth suppressive activities of p53 are a viable strategy for treating cancer; further studies are needed to address the true therapeutic potential of the approach.
Future Perspectives
A common theme emerging in cancer treatment is that combination therapy may be the ideal way to combat the problems of drug-related toxicity and resistance. While most attention has been paid to using drug combinations to activate distinct pathways, it is also possible to develop combinations of molecules that target a single specific pathway, given the fact that various small compounds with different chemical structures have been developed thus far. One might expect the synergistic effect of different p53 activators. Among the various wt p53 activators, nutlins have probably been the most studied in human cancers. While most of the efforts have focused on using nutlin-3 as a single agent for applications in oncology, some recent studies have also combined Nutlin-3 with chemotherapeutic agents and seen potentiation of activity of these chemotherapeutics in vitro, in acute myelogenous leukaemia, 47 multiple myeloma 48 and chronic lymphocytic leukaemia. 49 These initial studies definitely look promising and warrant more detailed studies in animal models. Their success would ultimately be evaluated by the response rates seen in patients in the clinic, either as individual agents in certain cases or in combination with standard chemotherapy in others.
Given the plethora of data supporting the therapeutic concept of p53 activation, there will be a realistic opportunity that the quest for small-molecule MDM2 antagonists in various combinations can translate into a clinical benefit in the near future.
